文献速递呼吸道感染呼吸危重症与机械通气

异基因造血干细胞移植后脓毒性休克:多中心ICU队列的结局与预后因素

Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation: Outcomes and Prognostic Factors in a Multicenter ICU Cohort.
PubMed 文献 · Chest · 2026-08-29

该多中心回顾性队列纳入2015至2020年ICU收治的异基因造血干细胞移植(allo-HSCT)后脓毒性休克患者,占ICU住院移植受者的38%(444/1164)。90天和3年死亡率分别为63%和81%。真菌病原学证据、SOFA评分和中性粒细胞缺乏与90天生存独立相关;早期氨基糖苷类使用与较高90天生存相关但随时间变化,不支持简单因果解读。

要点

  • allo-HSCT后脓毒性休克患者90天死亡率达63%,3年死亡率达81%。
  • 真菌病原学证据、SOFA评分和中性粒细胞缺乏是90天生存的独立预后因素。
  • 早期氨基糖苷类使用与较高90天生存相关,但时间变化分析提示关联复杂,需前瞻性验证。

核心结论

  • allo-HSCT后脓毒性休克死亡率高,90天死亡率为63%。
  • 预后主要由宿主相关因素和初始疾病严重程度驱动。
  • 氨基糖苷类使用与结局的关联复杂,不支持直接因果解释。

研究设计与样本

  • 多中心回顾性队列研究,纳入2015至2020年ICU收治的allo-HSCT后脓毒性休克受者。
  • 在1164例ICU住院的allo-HSCT受者中,444例(38%)因脓毒性休克入ICU。

主要发现

  • 中位SOFA评分为8(四分位距6-11)。
  • 62%(261例)获得微生物学证据,其中真菌病原体占17%(74例)。
  • 呼吸道是最常见感染来源(43%,180例)。
  • 64%(284例)需要有创机械通气,32%(143例)需要肾脏替代治疗。
  • 90天死亡率为63%(280例),3年死亡率为81%(350例)。

关键数值与推荐

  • 年龄≥56岁(HR 1.36,95%CI 0.99-1.87)、GVHD类型和早期细菌病原学证据(HR 0.90,95%CI 0.64-1.26)与90天生存无显著关联。

临床怎么用

  • 对allo-HSCT后脓毒性休克患者应识别真菌病原学证据、高SOFA评分和中性粒细胞缺乏等高危因素。
  • 早期氨基糖苷类使用与结局的关联需结合时间变化审慎解读,不宜直接推导因果。

局限性

  • 回顾性队列设计可能引入偏倚。
  • 氨基糖苷类使用与结局的关联随时间变化,不支持简单因果解释。
  • 氨基糖苷类与结局的关系需进一步前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Septic shock is a major cause of ICU admission among recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet data on its epidemiologic features and prognosis remain limited. RESEARCH QUESTION: What are the outcomes, independent prognostic factors, and associations of allo-HSCT that may inform early management? STUDY DESIGN AND METHODS: We performed a multicenter retrospective cohort study including recipients of allo-HSCT admitted to the ICU with septic shock between 2015 and 2020. RESULTS: Among 1,164 recipients of allo-HSCT hospitalized in ICU, 38% (n = 444) were admitted for septic shock. The median Sequential Organ Failure Assessment (SOFA) score was 8 (interquartile range, 6-11). Microbiological documentation was obtained in 62% (n = 261), including fungal pathogens in 17% (n = 74). The respiratory tract was the most common infection source (43%; n = 180). Invasive mechanical ventilation and renal replacement therapy were required in 64% (n = 284) and 32% (n = 143), respectively. Mortality at 90 days and 3 years was 63% (n = 280) and 81% (n = 350), respectively. In the extended Cox model, fungal documentation (hazard ratio [HR], 1.78 [95% CI, 1.19-2.67]; P = .005), SOFA score (HR, 1.07 [95% CI, 1.02-1.13]; P = .007), and neutropenia (HR, 3.94 [95% CI, 1.18-13.1]; P = .026) were associated independently with 90-day survival. In a 48-hour landmark analysis, early aminoglycoside use was associated with higher 90-day survival (HR, 0.46 [95% CI, 0.33-0.64]; P < .001). However, time-varying analyses indicated a nonconstant association over time. Age of ≥ 56 years (HR, 1.36 [95% CI, 0.99-1.87]), graft-versus-host disease type, and early bacterial documentation (HR, 0.90 [95% CI, 0.64-1.26]) were not associated with 90-day survival. INTERPRETATION: Our results show that septic shock after allo-HSCT carries a high mortality (63% at 90 days), largely driven by host-related factors and initial illness severity. The association between aminoglycoside use and outcome is complex, does not support a straightforward causal interpretation, and warrants further prospective evaluation.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Subileau M, Chean D, Dupont T, et al. Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation: Outcomes and Prognostic Factors in a Multicenter ICU Cohort. Chest. 2026. PMID: 42665126. doi:10.1016/j.chest.2026.06.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。